[A clinical trial of lansoprazole in the treatment of duodenal ulcer].

To evaluate the efficacy of a second generation acid pump inhibitor-lansoprazole (L) a controlled clinical trial in 72 patients of duodenal ulcer was carried out with omeprazole (O) as control. The results showed that the ulcer healing rate after 4-week treatment was 97.4% in lansoprazole group and 91.2% in omeprazole, while the effective rate was 100% and 97.1% respectively (P > 0.05). Ulcer related pain was relieved more quickly in lansoprazole group. The pain relief rate after treatment of 3 days was different significantly between the two group, being 74.3% (L) and 51.6% (O) respectively (P < 0.05). No marked side-effect was observed in lansoprazole group. It is shown that lansoprazole is effective and safe for treatment of duodenal ulcer.
AuthorsY Pei, B Wang, S Chen
JournalZhonghua nei ke za zhi (Zhonghua Nei Ke Za Zhi) Vol. 34 Issue 9 Pg. 606-8 (Sep 1995) ISSN: 0578-1426 [Print] CHINA
PMID8697927 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Comparative Study, English Abstract, Journal Article, Randomized Controlled Trial)
Chemical References
  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Ulcer Agents
  • Proton Pump Inhibitors
  • Lansoprazole
  • H(+)-K(+)-Exchanging ATPase
  • Omeprazole
  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Adult
  • Aged
  • Anti-Ulcer Agents (therapeutic use)
  • Duodenal Ulcer (drug therapy)
  • Female
  • H(+)-K(+)-Exchanging ATPase (therapeutic use)
  • Humans
  • Lansoprazole
  • Male
  • Middle Aged
  • Omeprazole (analogs & derivatives, therapeutic use)
  • Proton Pump Inhibitors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: